Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$15.3M
22M shares
52-week range
$0.36 – $2.58
15% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Adagio Medical Holdings Inc is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias with its proprietary, catheter-based Ultra-Low Temperature Ablation (ULTA) technology. UTLA is designed to create large, durable lesions extending through the depth of both diseased and healthy cardiac tissue. The company is currently focused on the treatment of ventricular tachycardia (VT), a rapid, abnormal heart rhythm, or arrhythmia, that originates in the heart's lower chambers, or ventricles. The company has one reportable segment.
www.adagiomedical.comNo one on the platform currently holds ADGM.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 16,557 | $19.0K |
No one on the platform has traded ADGM yet.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
@87trades Talking about Q4 & Q1 now on PMA approval. Would say they are less optimistic for year end which they said multiple times before. Also removed dates for acute data/full enrollment but added a conference as milestone 🤷 could be a longer way than expected with this stock $ADGM
View on StockTwits ↗$ADGM new investor deck just dropped. It’s a doozy. Basically pushed out substudy timeline 4-6 months. I bet they would like to have acute data at HRS 2027 (May). With no substudy news, it seems unlikely they get 6 mo. data by then. How will they get money and on what terms? https://investors.adagiomedical.com/static-files/7ba6d01c-496b-4f54-a5fa-318596176bb7
View on StockTwits ↗$ADGM two things stick out from Q1 10q (5/12/26) and Q2 10q (8/11/26): - Cash now sufficient until into Q4 (rather than Q3) - Addition of “strategic financing” in short-term May mean nothing but is worth noting. Disclosure: I’m long and have been for some time.
View on StockTwits ↗$ADGM adagio has meaningful technology but it will be eaten up by usability and scale of Medtronic. They need next gen trial to start but they are on hold until they get cash. Company seems content to wait. Will it be a mistake?
View on StockTwits ↗$ADGM hm, Q report without any real guidance. They urgently need cash, might only be sufficient until early Q4 - but imho they need it in September at the latest. Might wait for that FDA Day 100 meeting before a raise or partner stepping in.
View on StockTwits ↗$ADGM $RAIN next monster setting up on ticker AIFA! You don't want to miss this one bulls, has the recipe+DD to pull it off.
View on StockTwits ↗$AMIX, $ADGM, $ENSC, $CELZ Another good week with big gains for 9600 followers! All alerted premarket hours! 🔥🔥🔥🔥
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $0 | — | $-0.98 | $-1.26–$-0.67 | — | 1 |
| 2027 | $1M | — | $-0.86 | $-1.11–$-0.59 | — | 2 |
| 2028 | $7M | +442.3% | $-0.84 | $-1.61–$-0.19 | — | 3 |
| 2029 | $20M | +188.1% | $-3.32 | $-4.27–$-2.28 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| ADGMAdagio Medical Holdings, Inc. | $0.69 | -0.01% | $15M | — |
| ALURAllurion Technologies Inc. | $4.71 | -14.27% | $5M | — |
| ATHAAthira Pharma, Inc. | $6.75 | -6.12% | $27M | — |
| COCHEnvoy Medical, Inc. | $0.75 | +0.13% | $16M | — |
| CODXCo-Diagnostics, Inc. | $1.49 | +0.68% | $2M | — |
| CTXRCitius Pharmaceuticals, Inc. | $0.73 | -4.10% | $8M | — |
Source: Financial Modeling Prep · peers by sector/industry
| IRIXIRIDEX Corporation | $0.82 | -5.00% | $14M | — |